Connor, Clark & Lunn Investment Management (CC&L)’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-108,943	Closed	-$231K	–	1128
2018 Q3	$231K	Buy	108,943 +8,252	+8%	+$19.8K	﹤0.01%	828
2018 Q2	$233K	Buy	100,691 +38,091	+61%	+$111K	﹤0.01%	938
2018 Q1	$199K	Buy	62,600 +2,125	+4%	+$5.86K	﹤0.01%	657
2017 Q4	$248K	Sell	60,475 -9,425	-13%	-$41K	﹤0.01%	701
2017 Q3	$316K	Sell	69,900 -200	-0.3%	-$810	﹤0.01%	699
2017 Q2	$233K	Buy	+70,100	New	+$291K	﹤0.01%	715

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s OMED Position: Q4 2018 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2018, closing a stake of 108,943 shares — an estimated $231K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in OMED in Q2 2017 and held it in 6 quarters. The position peaked at $316K in Q3 2017. 42 funds tracked by Wall St. Rank hold OMED as of Q4 2018.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 108,943 OncoMed Pharmaceuticals, Inc. shares in Q4 2018, an estimated $231K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2017 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s OncoMed Pharmaceuticals, Inc. position peaked at $316K in Q3 2017.
42 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2018.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2018, filed 12 Feb 2019.